Unknown PHASE1 INTERVENTIONAL 6-arm NCT02188810

Safety and Reactogenicity of a PAL Combined With Seasonal Flu Vaccine in Healthy Adults

A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (FB-631) Co-administered With Seasonal TIV (2013-2014) in Healthy Adults.

Sponsor: Folia Biotech Inc.

Conditions Flu

Interventions PAL TIV

Updated 6 times since 2017 Last updated: Feb 11, 2016 Started: Apr 30, 2014 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Flu, this trial is ongoing. The trial is conducted by Folia Biotech Inc. and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Mar 2018 — Jun 2018 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Folia Biotech Inc.

Data source: Folia Biotech Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Halifax, Canada